Back to discover

Protein / target

Potassium channel subfamily K member 2

Encoded byKCNK2O95069Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
5
Approved medicines
Open Targets target-level
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Outward rectifier potassium channel

Strongest disease association

Arthritis, Psoriatic

Via encoding gene KCNK2 · Genetic evidence · score 0.65

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

K(+) channel that conducts voltage-dependent outward rectifying currents upon membrane depolarization.

View complete UniProt function annotation

K(+) channel that conducts voltage-dependent outward rectifying currents upon membrane depolarization. Voltage sensing is coupled to K(+) electrochemical gradient in an 'ion flux gating' mode where outward but not inward ion flow opens the gate. Converts to voltage-independent 'leak' conductance mode upon stimulation by various stimuli including mechanical membrane stretch, acidic pH, heat and lipids. Reversibly converts between a voltage-insensitive K(+) 'leak' channel and a voltage-dependent outward rectifying K(+) channel in a phosphorylation-dependent manner (By similarity) (PubMed:10321245, PubMed:10784345, PubMed:11319556, PubMed:23169818, PubMed:30573346, PubMed:38605031). Homo- and heterodimerizes to form functional channels with distinct regulatory and gating properties (By similarity). In trigeminal ganglia sensory neurons, the heterodimer of KCNK2/TREK-1 and KCNK18/TRESK inhibits neuronal firing and neurogenic inflammation by stabilizing the resting membrane potential at K(+) equilibrium potential as well as by regulating the threshold of action potentials and the spike frequency (By similarity). At trigeminal A-beta afferent nerves, the heterodimer of KCNK2/TREK-1 and KCNK4/TRAAK is mostly coexpressed at nodes of Ranvier where it conducts voltage-independent mechanosensitive and thermosensitive currents, allowing rapid action potential repolarization, high speed and high frequence saltatory conduction on myelinated nerves to ensure prompt sensory responses (By similarity). In hippocampal astrocytes, the heterodimer of KCNK2/TREK-1 and KCNK1/TWIK-1 allows passive K(+) conductance under basal conditions, but changes ion selectivity and becomes permeable to L-glutamate and Cl(-) ions upon binding to G protein subunit GNG4 in stimulated astrocytes. Mediates rapid L-glutamate release in response to activation of G protein-coupled receptors, such as F2R and CNR1 (By similarity). In hippocampal pyramidal neurons, the homodimer of KCNK2/TREK-1 contributes to gamma-aminobutyric acid (GABA) B-induced slow inhibitory postsynaptic potential. Associates with AKAP5 and Gs-protein-coupled receptor B2AR at postsynaptic dense bodies and converts to a leak channel no longer sensitive to stimulation by arachidonic acid, acidic pH or mechanical stress, nor inhibited by Gq-coupled receptors but still under the negative control of Gs-coupled receptors (By similarity). Permeable to other monovalent cations such as Rb(+) and Cs(+) (By similarity)

Subcellular location

Cell membraneEndoplasmic reticulum membraneCell projection, axonCell projection, dendritePostsynaptic density membraneCell membrane, sarcolemma
Domains and Gene Ontology detail (38)

Gene Ontology

  • Capical plasma membrane
  • Castrocyte projection
  • Ccalyx of Held
  • Ccell surface
  • Cdendrite
  • Cendoplasmic reticulum
  • Cendoplasmic reticulum membrane
  • Cneuronal cell body
  • Cnode of Ranvier
  • Cplasma membrane
  • Cpostsynaptic density membrane
  • Csarcolemma

426 aa · 47 kDa · 4 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Inhibitory neurotransmissionUniProt · GOIon channel gatingGOLigand-gated signallingGO
View supporting evidence

Inhibitory neurotransmission

  • ·K(+) channel that conducts voltage-dependent outward rectifying currents upon membrane d…
  • ·regulation of synaptic transmission, GABAergic

Ion channel gating

  • ·ligand-gated channel activity
  • ·potassium ion transmembrane transport

Ligand-gated signalling

  • ·ligand-gated channel activity
View underlying pathways (2)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

KCNK1KCNK10PRKACGPRKACBPRKACAKRT76KCNK4POPDC2BVESPIEZO1KCNK2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

3

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Isoflurane
ApprovedOpener

Potassium channel subfamily K member 2 opener

Direct interaction with this protein · 1 of 23 recorded protein targets — broad pharmacology

Halothane
ApprovedOpener

Potassium channel subfamily K member 2 opener

Direct interaction with this protein · 1 of 23 recorded protein targets — broad pharmacology

sevoflurane
ApprovedOpener

Potassium channel subfamily K member 2 opener

Direct interaction with this protein · 1 of 23 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene KCNK2

Gene-level evidence surfaced through the gene KCNK2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Arthritis, Psoriatic
0.65Moderately supported

Genetic evidence dominant · Open Targets 0.40

Hypertension
0.61Moderately supported

Genetic evidence dominant · Open Targets 0.37

Male reproductive organ cancer
0.53Moderately supported

Genetic evidence dominant · Open Targets 0.32

Female reproductive system disorder
0.53Moderately supported

Genetic evidence dominant · Open Targets 0.32

Respiratory Distress Syndrome
0.47Limited support

Clinical evidence dominant · Open Targets 0.38

View evidence synthesis (5)
Arthritis, PsoriaticModerately supported
0.65
agreement 0.530.77
Genetic100%

Open Targets aggregate 0.40 · 1 independent evidence family

HypertensionModerately supported
0.61
agreement 0.470.75
Genetic98%Literature2%

Open Targets aggregate 0.37 · 2 independent evidence families

Male reproductive organ cancerModerately supported
0.53
agreement 0.390.67
Genetic100%Literature0%

Open Targets aggregate 0.32 · 2 independent evidence families

Female reproductive system disorderModerately supported
0.53
agreement 0.410.65
Genetic100%

Open Targets aggregate 0.32 · 1 independent evidence family

Respiratory Distress SyndromeLimited support
0.47
agreement 0.320.63
Clinical97%Literature4%

Open Targets aggregate 0.38 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Arthritis, Psoriatic0.40
Respiratory Distress Syndrome0.38
Hypertension0.37
Male reproductive organ cancer0.32
Female reproductive system disorder0.32

Drug development

5 compounds recorded · 5 approved

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 3 drugs that target this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (5)
HALOTHANEApproval
SEVOFLURANEApproval
DESFLURANEApproval
ENFLURANEApproval
ISOFLURANEApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (9)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

NOT_YET_RECRUITING · via sevoflurane · NCT07035782

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. New publication2025-02-08
    Neonatal sevoflurane exposures inhibits DHHC5-mediated palmitoylation of TfR1 in oligodendrocytes, leading to hypomyelination and neurological impairments.

    Journal of advanced research · 2025 · 9 citations · Europe PMC · via sevoflurane

  2. New publication2003-02-01
    Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits.

    The Journal of neuroscience : the official journal of the Society for Neuroscience · 2003 · 1,387 citations · Europe PMC · via Isoflurane

  3. New publication1995-01-01
    Sharp wave-associated high-frequency oscillation (200 Hz) in the intact hippocampus: network and intracellular mechanisms.

    The Journal of neuroscience : the official journal of the Society for Neuroscience · 1995 · 798 citations · Europe PMC · via Halothane

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.